Provided by Tiger Fintech (Singapore) Pte. Ltd.

Recursion Pharmaceuticals, Inc.

5.84
+0.11001.92%
Post-market: 5.81-0.0300-0.51%19:59 EDT
Volume:13.83M
Turnover:80.83M
Market Cap:2.35B
PE:-3.45
High:6.07
Open:5.78
Low:5.68
Close:5.73
Loading ...

Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing

Zacks
·
5 hours ago

Press Release: Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Dow Jones
·
Yesterday

Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards?

Zacks
·
25 Apr

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

GlobeNewswire
·
23 Apr

Recursion Pharmaceuticals (RXRX) Stock Moves -1.64%: What You Should Know

Zacks
·
22 Apr

Recursion Pharmaceuticals (NasdaqGS:RXRX) Taps Real-World Data With HealthVerity Licensing Deal

Simply Wall St.
·
19 Apr

BRIEF-Healthverity Partners With Recursion To Enhance Clinical Trial Analytics With Real-World Data

Reuters
·
16 Apr

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

PR Newswire
·
16 Apr

Why Recursion Pharmaceuticals, Inc. (RXRX) Went Down On Monday?

Insider Monkey
·
15 Apr

Cathie Wood’s ARK Investment buys 460K shares of Recursion Pharmaceuticals today

TIPRANKS
·
15 Apr

Jim Cramer on Recursion (RXRX): “The AI Company That Has It – Backed by Jensen Huang and NVIDIA”

Insider Monkey
·
15 Apr

Strength Seen in Recursion Pharmaceuticals (RXRX): Can Its 27.7% Jump Turn into More Strength?

Zacks
·
14 Apr

Analysts Offer Insights on Healthcare Companies: Recursion Pharmaceuticals (RXRX) and Bruker (BRKR)

TIPRANKS
·
13 Apr

Recursion Pharmaceuticals call volume above normal and directionally bullish

TIPRANKS
·
12 Apr

Shares of AI-Based Drug Developers up on US FDA's Plans to Replace Animal Testing

THOMSON REUTERS
·
11 Apr

Recursion Pharmaceuticals up 9.3%, Absci up 10.9%, Schrodinger up 4.5% and Certara up 10.9%

THOMSON REUTERS
·
11 Apr

AI Biotech Stocks Shined. Recursion Soared 20% And Absci Surged 13%

Tiger Newspress
·
11 Apr

US FDA to Phase Out Animal Testing in Drug Development, Adopt AI Methods

Reuters
·
11 Apr

Recursion Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley

Dow Jones
·
11 Apr

Recursion Pharmaceuticals price target lowered to $8 from $10 at Morgan Stanley

TIPRANKS
·
10 Apr